EU safety review for Novartis's Gilenya
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has announced the start of a review of Novartis's multiple sclerosis treatment Gilenya (fingolimod) following cardiac safety concerns, and is advising increased monitoring of all new patients while it awaits the results.